Biocon Moat Analysis: Score & Risks
Biocon Ltd.
A first-pass moat teardown of Biocon Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Intangible Assets. Provisional, single-pass evidence.
Biocon Ltd. scores 5.57 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“A fully digitized quality organization, together with a strong regulatory track record, supports robust data integrity and consistent outcomes for customers worldwide”
“It is capitalizing on its ‘lab to market’ capabilities to serve over 6.3 million patients across 120+ countries by enabling affordable access to high quality biosimilars.”
“The recent commissioning of state-of-the-art facilities is expected to improve margins as demand ramps up, and capacity utilization increases.”
“BMS partnership extended through to 2035, expanded scope across discovery, development, manufacturing and clinical services”
“India advantage: Cost efficiency, technical talent pool; India gearing to upgrade its innovation ecosystem e.g., $600 Mn of Govt funding, 12 Biotech parks being set up)”
“Portfolio of 30+ biosimilars and 3 GLP-1s addressing a total market opportunity of $200B+1”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6.0 — clears the gate. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 113 Indian companies we have scored for moat durability — 88 narrow, 25 narrow-trending-wide, none wide. The full ranked read: Wide-Moat Stocks in India: We Scored 113 Companies and Found None. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion